Illumina, Inc. (NASDAQ:ILMN) Shares Bought by BNP Paribas Financial Markets

BNP Paribas Financial Markets lifted its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 100.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 590,287 shares of the life sciences company’s stock after purchasing an additional 295,896 shares during the quarter. BNP Paribas Financial Markets’ holdings in Illumina were worth $78,880,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Capital World Investors grew its holdings in Illumina by 408.6% in the 4th quarter. Capital World Investors now owns 18,025,301 shares of the life sciences company’s stock valued at $2,408,721,000 after buying an additional 14,481,232 shares during the period. Norges Bank purchased a new stake in Illumina in the fourth quarter valued at approximately $228,714,000. Bessemer Group Inc. increased its position in Illumina by 32,837.5% during the fourth quarter. Bessemer Group Inc. now owns 1,348,131 shares of the life sciences company’s stock worth $180,152,000 after purchasing an additional 1,344,038 shares during the last quarter. WCM Investment Management LLC raised its stake in Illumina by 26.6% during the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock worth $551,625,000 after purchasing an additional 867,673 shares during the period. Finally, Pictet Asset Management Holding SA boosted its holdings in shares of Illumina by 245.7% in the 4th quarter. Pictet Asset Management Holding SA now owns 1,182,454 shares of the life sciences company’s stock valued at $158,011,000 after purchasing an additional 840,423 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently commented on ILMN shares. Royal Bank of Canada dropped their price objective on Illumina from $128.00 to $112.00 and set an “outperform” rating for the company in a report on Tuesday, April 8th. Citigroup cut their price objective on Illumina from $90.00 to $85.00 and set a “neutral” rating on the stock in a report on Monday, April 7th. Guggenheim decreased their target price on Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a report on Friday, February 7th. Hsbc Global Res downgraded shares of Illumina from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 28th. Finally, Robert W. Baird reduced their price target on shares of Illumina from $127.00 to $90.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 5th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Illumina has an average rating of “Moderate Buy” and a consensus price target of $137.55.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $78.17 on Tuesday. The business has a 50 day moving average price of $79.75 and a two-hundred day moving average price of $114.99. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66. The firm has a market cap of $12.37 billion, a PE ratio of -10.18, a price-to-earnings-growth ratio of 1.60 and a beta of 1.35. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Sell-side analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.